Smith Group Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Smith Group Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-35,314	Closed	-$434K	–	561
2015 Q4	$434K	Sell	35,314 -5,593	-14%	-$74.7K	0.01%	208
2015 Q3	$597K	Sell	40,907 -8	-0%	-$138	0.02%	190
2015 Q2	$798K	Buy	+40,915	New	+$790K	0.03%	182

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Smith Group Asset Management's CTIC Position: Q1 2016 in Review

Smith Group Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2016, closing a stake of 35,314 shares — an estimated $434K sold.

Smith Group Asset Management first reported a position in CTIC in Q2 2015 and held it in 3 quarters. The position peaked at $798K in Q2 2015. 80 funds tracked by Wall St. Rank hold CTIC as of Q1 2016.

Smith Group Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2016 after selling out during the quarter.
Smith Group Asset Management sold 35,314 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2016, an estimated $434K.
Smith Group Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2015 and held it in 3 quarters.
Smith Group Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $798K in Q2 2015.
80 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2016.

Based on Smith Group Asset Management's 13F filing for Q1 2016, filed 3 May 2016.